 |
||||||||||||
|
ABOUT
UPSTREAM Our initial candidate genetic predisposition markers are targeted against liver, prostate, ovarian and thyroid cancer with a market potential of over one billion dollars and can complement existing detection tests. Upstream’s proprietary data mining pipeline and assay generate candidate genetic biomarkers. OUR MANAGEMENT TEAM: Upstream's management team has over thirty years of combined experience in the biotech sector. Joel Bellenson, CEO & Director Founded Market Leading Companies:
Created Market Defining Products:
Track-record of Successful Fundraising:
In 2004, Mr. Fernback left Wolverton Securities and was the founder of a boutique technology consulting practice. Since 2002, Mr. Fernback has been an active director of the Okanagan Capital Fund, an Okanagan-based technology venture fund. Mr. Fernback is a graduate of McMaster University, where he studied molecular biology and biochemistry, and also a graduate of the University of British Columbia, where he completed his MBA with a concentration in Finance. At Upstream Biosciences Inc., Mr. Fernback is responsible for directing, identifying and evaluating strategic financing and partnering opportunities for the Company. Mr. Fernback contributes to the establishment of the overall business support by working closely with the senior management team.
|
| ||||||||||
Joel
Lloyd Bellenson, Co-founder, Chairman, CEO &
Director was the co-founder and CEO of DoubleTwist, formerly the
world's leading bioinformatics company. Bellenson was also Co-founder
and CEO of DigiScents, internationally known for sequencing and using
the human olfactory receptors to digitize the sense of smell. Bellenson
is a graduate of Stanford University, where he studied molecular biology
and international relations. He co-founded and managed the high-throughput
DNA Analysis Facility at Stanford University Medical Center from 1989
to 1993 under Nobel Prize laureate Dr. Paul Berg. Bellenson wrote the
bioinformatics chapter to the groundbreaking 1998 book, “DNA Microarrays,
a Practical Approach,” Schena, et.al.
Dexster
L. Smith, Co-founder, President & Director was
co-founder and President of DoubleTwist, formerly the world's leading
bioinformatics company. Smith was also Co-founder and President of DigiScents,
internationally known for sequencing and using the human olfactory receptors
to digitize the sense of smell. Smith is a graduate of Stanford University,
where he studied industrial engineering and computer science.
Tim
Fernback: CFO, has over a decade of experience financing
both private and public companies in Canada. Mr. Fernback was the head
of the technology consulting practice for Discovery Capital Corporation,
a prominent British Columbia venture capital firm specializing in financing
and consulting to technology based start-up ventures, and later ran
the Investment Banking/ Corporate Finance Departments for the oldest
and most respected Western Canadian based brokerage firm, Wolverton
Securities Ltd.